Docket No. PRD-0032-USPCT1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mercken et al.

Int'l Appln. No.: PCT/EP2003/010092

Serial No. : Unassigned

Art Unit: Unassigned

Filed

: I.A. 09.09.2003

Examiner: Unassigned

For

: N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES,

COMPOSITIONS, METHODS AND USES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 23, 2005
(Date of Deposit)

Laura A. Donnelly
(Name of applicant, assignee, or Registered Representative)

fame C. Honnely

March 23, 2005

(Date of Signature)

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Sta	tement in Accordance with §1.97(e)
(at	tached); or
☐ Ple	ase charge Deposit Account No. 10-
075	0/ / the fee of \$180.00 as set forth
in	§1.17(p).
_	dance with §1.97(d), this Information
	nt is being filed after the mailing date of
	ion under §1.113 or a Notice of Allowance
	pefore the payment of the Issue Fee.
Applicant(s) hereby	petition(s) for consideration of this
Information Disclos	sure Statement. Included are: Statement in
Accordance with §1	.97(e) as set forth below and the fee of
\$180.00 as set for	th in §1.17(p).
_	f each of the references listed on the 1449 are enclosed herewith.
☐ Copies o	f references listed on the attached Form PTC
1449 are enclosed	nerewith EXCEPT THAT:
☐ In	view of the voluminous nature of references
[li	st as appropriate], and the likelihood that
the	se references are available to the Examiner,
сор	ies are not enclosed herewith.
☐ If	any of the foregoing publications are not
ava	ilable to the Examiner, Applicant will
end	eavor to supply copies at the Examiner's
req	uest.
☐ Copies o	f only foreign patent documents and non-
patent literature	are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S.	patents and each U.S. patent application
publication listed	on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

 \square There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-0032-USPCT1/LAD. This form is submitted in triplicate.

Respectfully submitted,

Laura A. Donnelly Reg. No. 38,435

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729
DATED: March 23, 2005



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
as collection of information unless it displays a valid OMB crafted mighter.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB costile number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information diffess it displays a value of the cost of information.					
Application Number	Unassigned 2 40 7				
Filing Date	March 23, 2005				
First Named Inventor	Mercken et al.				
Group Art Unit	Unassigned				
Examiner Name	Unassigned				
Attorney Docket Number	PRD-0032-USPCT1				

			et i di z	U.S. PATENT DOCUMENTS				
	U.S. Patent Document							
Funminas		U.S. Paterit Do	Kind Code ²	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,		
Examiner Initials	Cite No. ¹	Number	(if known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages of relevant figures appear		
				 				
			- - 					
	ļ							
_	ļ							
	1							
	 							
	-							
<u> </u>								
			-0.0					


FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Foreign Patent Document Date of Publication of Cited Document where relevant Name of Patentee or passages or relevant T⁶ Cite Examiner mm-dd-yyyy Applicant of Cited Document figures appear KindCode⁵ Initials Office³ Number⁴ WO 01/62801 A2 30.08.2001 Washington University

	 	_
Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

Unassigned 5 20 0
March 23, 2005
Mercken et al.
Unassigned
Unassigned
PRD-0032-USPCT1

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ²			
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
		Saido et al., "Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain", Neuroscience Letters, Vol. 215, No. 3, pp. 173-176 (1996).				
	•	Naslund et al., "Relative Abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging", Proceedings of the National Academy of Sciences of the United States, Vol. 91, No. 18, pp. 8378-8382 (1994).				
		Vassar et al., "β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE", Science, Vol. 286, No. 5440, pp. 735-741 (1999).				
		·				

Examiner	l Date	i	
LAGITIMICI			
Cionatura	Considered		
Signature		J	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number Unassigned / Silling Date March 23, 2005

First Named Inventor Mercken et al.

Group Art Unit Unassigned

Examiner Name Unassigned

Attorney Docket Number PRD-0032-USPCT1

Page 1 of 1

-112			U.S. Patent Docum	ent	
Examiner Initials	1 Cite 1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
_,	-		 		
					

		FOREIC	IN PATENT	DOCUMEN	NTS		
Examiner Initials	Name of Patentee or where rel xaminer Cite Applicant of Cited Document 2 2 2 3 2 2 4 20 5 5		Pages, Columns, Lines, where relevant passages or relevant figures appear	.™			
		OTHER PRIOR ART -					
Examiner 's Initials*	Cite No.1	Include name of the author (in title of the item (book, magazir volume-issue number	ne, journal, se (s), publisher	erial, symper, city and/o	osium, catalo or country wh	og, etc.), date, page(s), ere published	T²
		International Search Report dated PCT/EP2003/010092	February 1	I, 2004 fo	r related Int	ernational Application No.	

Examiner	Date	
Signature	Considered	